MERIDIAN, ID , a developer, manufacturer, and marketer of specialty generic prescription drug products, today announced it will file a Form 12b-25 with the Security and Exchange Commission for an automatic five-day extension to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. The Company requires additional time to complete certain statements and expects to report its 2008 First Quarter financial results on Monday, May 19, 2008.

The Company plans a conference call at 11:00 a.m. ET on Tuesday, May 20, 2008 to discuss the report. Hosting the call will be RxElite CEO Jonathan Houssian, COO Earl E. Sullivan, and VP of Finance Shannon M. Stith.

Conference Call

To participate in the conference call, callers from the USA please dial toll free 1(866) 261-3331, all other international calls please dial 1(703) 639-1225. All callers should dial in five to ten minutes prior to the conference call time.

Audio Stream

Rebroadcast of the audio stream will be available at http://www.rxelite.com for 90 days after the initial broadcast. Click on the Investor Relations tab and First Quarter 2008 Conference Call.

About RxElite, Inc.

RxElite, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), complex active pharmaceutical ingredients, and other specialty areas. www.RxElite.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.

Corporate Information Ph: (208) 288-5550 Toll Free: (800) 414-1901 Fax: (208) 288-1191 Investor Relations PH: (208) 288-5550 Fax: (208) 288-1191 Email: Email Contact

RXElite (CE) (USOTC:RXEI)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more RXElite (CE) Charts.
RXElite (CE) (USOTC:RXEI)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more RXElite (CE) Charts.